Orally-Administered Caspase Inhibitor PF-03491390 Is Retained in the Liver for Prolonged Periods With Low Systemic Exposure, Exerting a Hepatoprotective Effect Against α-Fas-Induced Liver Injury in a Mouse Model

• Main Authors: Yoshinobu Ueno (Author), Takashi Ohmi (Author), Mitsuko Yamamoto (Author), Naoto Kato (Author), Yukiko Moriguchi (Author), Midori Kojima (Author), Rieko Shimozono (Author), Sachiko Suzuki (Author), Tomomi Matsuura (Author), Hiroyuki Eda (Author)
• Format: Book
• Published: Elsevier, 2007-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

In a mouse model of α-Fas-induced acute liver injury, the orally-administered caspase inhibitor PF-03491390 (formerly named IDN-6556) was retained in the liver for prolonged periods with a low systemic exposure. Reductions in the elevated plasma levels of alanine aminotransferase (ALT) revealed that...